Tesamorelin — Synthetic Peptide Research Compound

Catalog ID: TESA | CAS: 218949-48-5 | Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Gln-Ser-Ser-Gly-Ala-Gly-Ser-Gly-Ala-Pro-Gly-Lys-Lys-NH₂

Compound Overview

Tesamorelin is a synthetic peptide analog of human Growth Hormone–Releasing Hormone (GHRH).
It is used in preclinical research to study growth hormone axis regulation, pituitary receptor interactions, and peptide-based endocrine signaling.
Not for human consumption or therapeutic use.

Molecular Characteristics

• Synonyms: Egrifta® (research name), GHRH (1–44) analog
• CAS Number: 218949-48-5
• Sequence: 44-amino-acid peptide analog of human GHRH
• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular Weight: ≈ 5135.9 g/mol
• Purity: ≥ 98% (HPLC)
• Formulation: Lyophilized peptide powder

Physical Properties

• Appearance: White to off-white lyophilized powder
• Solubility: Sterile water or 0.6 % acetic acid (research use only)
• Container: Sterile sealed vial

Storage & Stability

• Unreconstituted: Store at −20 °C, protected from light and moisture.
• Reconstituted: Aliquot and store at −20 °C; avoid repeated freeze–thaw cycles.

Research Context

Tesamorelin is investigated in laboratory models for its effects on pituitary receptor binding, cyclic AMP (cAMP) activation, and downstream somatotropic gene expression.
It serves as a reference analog for growth hormone–releasing hormone (GHRH) peptide interaction studies and structure–function mapping within endocrine